Psyence Group (TSE:PSYG) has released an update.
Psyence Group, a biotech firm focused on psilocybin for mental health, has successfully exported its drug candidate PEX010 to Australia for a Phase IIb clinical trial. The trial will compare two doses of the compound alongside psychotherapy in the treatment of Adjustment Disorder in palliative care. Additionally, Psyence Biomed has ended a commercial term sheet with Filament Health, but the partnership continues for the trial’s supply needs while exploring other supply and license agreements.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.
